Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Ocean Power Technologies Partners with Unique Group for Autonomous Vehicle Services in the Middle East
-
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
-
Ackroo Confirms Commencement Date for Normal Course Issuer Bid
-
Scientific Presentations Highlight OGM’s Utility for Cancer Research at Joint Annual Meeting for Three Molecular and Cytogenetic Associations
-
NAV Announcement and Portfolio Company Update
-
Portfolio and NAV Update
-
CEO Letter to Shareholders
-
Half-year statement of the Liquidity Contract entered into with Oddo BHF SCA
-
Dr. Gabriele Weichert takes the helm as President of the Canadian Dermatology Association
-
Stream Companies to join Kia Canada's Premier SEO Content Marketing Solutions Program
-
Probe Gold Strengthens Technical Team with the Appointment of VP Exploration
-
Marktuk Unveils AI-Powered Personal Financial Planning App for Seamless Savings and Investing
-
Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
-
Marimaca Announces Channel Sample Results from Mercedes Satellite Target
-
Spectral Medical Provides June Tigris Trial Update
-
Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
-
AYR Wellness to Hold Second Quarter 2024 Conference Call on August 7 at 8:00 a.m. ET
-
Kforce Inc. Announces Date of Second Quarter Earnings Results and Conference Call
-
MariMed Closes Acquisition of Second Maryland Dispensary
-
Altimmune to Participate at Leerink Partners Therapeutics Forum
-
Dragonfly Energy Empowers Youth with Actor Jeremy Renner and The John Lennon Educational Tour Bus on an Original Project
-
Streamline Health® Announces New eValuator™ Contract with 750-Bed Academic Medical Center
-
Bombardier Statement Regarding Aerostructures Produced by Spirit Aerosystems
-
Amerigo Announces Board of Director Changes
-
Terranet has conducted prototype tests of BlincVision in a vehicle outdoors during the second quarter
-
O-I Glass Plans Technology & Sustainability Transformation of its Alloa, UK Plant
-
O-I Glass Plans Technology & Sustainability Transformation of its Alloa, UK Plant
-
Gilat Awarded Over $9M to Support Critical Connectivity Requirements for the US Department of Defense
-
Xtract One’s SmartGateway Completes Operational Test & Evaluation by National Safe Skies Alliance, Inc. for Airport Security
-
Endeavor Venture Funds and Keiretsu Forum Forge Strategic Alliance to Enhance Early-Stage Investment Opportunities
-
Nasdaq Welcomes 66 IPOs in the First Half of 2024
-
Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
-
Aya Gold & Silver Announces At-Depth High-Grade Drill Results at Zgounder
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Black Diamond Group Limited Announces Modular Space Solutions Asset Purchase in British Columbia
-
Beneficient Announces Termination of SEC Investigation
-
Eclipse Foundation Releases the Industry’s First Survey of Open Source Developers and Policymakers from the Global South
-
Green Shift Commodities Completes Sale of Argentina Lithium Assets
-
CytoSorbents Secures $20 Million Credit Facility
-
Verano to Report Second Quarter 2024 Financial Results on August 7, 2024
-
Chris-Craft Introduces New Sportster 25
-
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
-
ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP
-
PyroGenesis Provides Responses to Investor Questions
-
Tecnoglass Attains Carbon Neutrality, Reinforcing Its Commitment to Sustainable Practices
-
Sitryx announces leadership transition
-
Dimensional Fund Advisors Ltd. : Form 8.3 - BARRATT DEVELOPMENTS PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - DS SMITH PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - HARGREAVES LANSDOWN PLC - Ordinary Shares
-
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
